deltatrials
Completed PHASE4 NCT00773708

Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed Product

Pilot Study to Assess the Role of Immune Activation and Apoptosis as a Marker for Treatment Intensification With Raltegravir in Hiv-infected Patients on Antiretroviral Therapy With Long-term Viral Suppression and Unfavourable Immunologic Response (Discordant Patients: v+i-)

Sponsor: Germans Trias i Pujol Hospital

Conditions HIV Infections
Interventions raltegravir
Updated 5 times since 2017 Last updated: Mar 10, 2015 Started: Mar 31, 2009 Primary completion: May 31, 2011 Completion: May 31, 2011

Listed as NCT00773708, this PHASE4 trial focuses on HIV Infections and remains completed. Sponsored by Germans Trias i Pujol Hospital, it has been updated 5 times since 2009, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE4

    First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Germans Trias i Pujol Hospital
Data source: Germans Trias i Pujol Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Badalona, Spain